Five Questions About the Future of Gene Editing
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]
In Case You Missed It: Three Things We Learned From the Evaluate Vantage 2023 Preview Webinar
Missed out latest webinar? Fear not, here are three things we learned from the 2023 Preview discussion. And the webinar is available on demand now. It is now officially too late to say “Happy new year” to people you’ve not seen since December, but it’s not quite too late to be looking ahead to what […]
More in Hope than Expectation: Biopharma in 2023
Few people are expecting biopharma to stage a spectacular comeback in 2023 but what can we reasonably hope for – and when? I joined the world of biopharma in 2022 and it seems I didn’t pick a vintage year. M&A activity was weak, share prices plummeted and IPOs were all but non-existent. However, I have […]
What to expect from JP Morgan 2023
The real start to the biopharma year, the JP Morgan Healthcare Conference, is nearly upon us. As the holidays fade into memory – along with a pretty rough 2022 – what will this bellwether of the industry bring? I caught up with one of Evaluate’s VP consultants, Vinay Bhaskar, who’ll be in San Francisco as […]
Medtech in 2028: Suffering or Celebrating a COVID Hangover?
We’ve extended our forecasts out to 2028 and in our latest report, we take a look at what’s in store for the medtech market in the next few years. It seems obvious to say that Covid had a massive impact on the medtech industry but being obvious doesn’t stop the statement being true. Several […]
Five Things You’re Getting Wrong in Your Pipeline Planning
R&D pipelines are the lifeblood of the pharma industry – so why are we still getting it wrong? More so than perhaps any other industry, the product pipeline is critical to pharma and biotech businesses. Long R&D timelines, regulatory hurdles, patent expirations and an ever-changing competitive landscape means that no company can afford to […]
Biotech Investment in 2022 : “You’ve Got to Kiss a Lot of Frogs”
The market may be tough, but with unprecedented innovation taking place, there’s plenty for biotechs and investors to feel positive about in the long term. You may (or indeed may not) have seen our recent webinar, Tricky Terrain: Navigating the pharma investment landscape. If you did miss it, check it out to get a quick […]
BIO International 2022: Words From Space and Venus
Bio International was finally back for 2022. What did our first-timer to the event make of it? As a newcomer to the pharma and biotech industry, I was excited not only to be attending Bio International, but my first in-person convention in a while. It was a great feeling to be back on an exhibition […]
Biotech Terrain May Be Tricky, but It’s Worth Persevering
What are venture capitalists looking for from the biotech and pharma space? It is fair to say that the biotech market is having a challenging time. Much has been written about the lack of M&A activity, disappointing stock performances and the closing of the IPO window as those companies that have managed to get away […]
Five Reasons You Can’t Ignore Payers During Pipeline Development
Could previously launched drugs that significantly missed sales expectations have met a different fate if their manufacturers had accounted for payer perspectives in their early-stage development strategy? Let’s start with some stats. About half of the drugs launched in the last 15 years underperformed analysts’ sales estimates by more than 20%1. Only one-fifth of […]
